 |
|
TERRAMYCIN IN TREATMENT OF HUMAN BRUCELLOSIS
VERNON KNIGHT, M.D.;
FRANCISCO RUIZ SANCHEZ, M.D.;
AMADO RUIZ SANCHEZ, M.D.
AMA Arch Intern Med. 1951;87(6):835-843.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
CONVINCING evidence is now available to indicate that aureomycin and chloramphenicol are effective in suppressing the acute manifestations of brucellosis.1 Substantial numbers of patients have had prompt clinical remissions of the acute illness following treatment with both these agents. Despite improvement in treatment of the acute infection, however, there remains a serious therapeutic problem in the occurrence of an appreciable number of relapses. In the several series reported, including those described by us, the rate of relapse has ranged from less than one fourth to approximately one half of the total patients treated. Among the many factors which may influence the relapse rate is one common to virtually all the aforementioned studies, namely, a limitation of the total length of antimicrobial therapy to a period of about two weeks or less. In these various studies the regimens of therapy were principally determined by the amount of drug available, and
. . . [Full Text PDF of this Article]
Author Affiliations
NEW YORK; GUADALAJARA, MEXICO
From the Laboratory for Research in Infectious Disease, University of Guadalajara Medical School, Guadalajara, Mexico, and the Department of Medicine, New York Hospital— Cornell University Medical Center, New York.
Footnotes
Presented in part before the Terramycin Symposium of the New York Academy of Science, New York, June 16, 1950.
Dr. Knight was formerly postdoctorate Research Fellow, National Institutes of Health, United States Public Health Service.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
